Tags

Type your tag names separated by a space and hit enter

Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Mov Disord. 1996 May; 11(3):257-60.MD

Abstract

The ergoline derivative FCE 23,884 acts as a dopamine D1 agonist in untreated parkinsonian animals and as a D2 antagonist in animals whose dopamine system is intact or levodopa treated. To evaluate whether this dual action might benefit patients with Parkinson's disease (PD) who have developed levodopa-induced dyskinesias, the motor effects of FCE 23,884 were examined in seven such individuals using a double-blind, placebo-controlled design. At doses up to the maximum tolerated dose (3.5 +/- 0.5 mg), FCE 23,884 monotherapy did not affect parkinsonian severity. On the other hand, coadministration of FCE 23,884 with a mildly dyskinetic dose of levodopa, infused intravenously under steady-state conditions, reduced the antiparkinson response by 54 +/- 19% and tended to diminish dyskinesia severity. The results thus fail to suggest any useful role for FCE 23,884 in the symptomatic treatment of PD. Although D2 receptor blockade provided by FCE 23,884 antagonizes both the antiparkinson and dyskinesigenic responses to levodopa, the degree of D1 receptor stimulation appears insufficient to ameliorate parkinsonian symptomatology.

Authors+Show Affiliations

Metman LV
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA.
Blanchet PJ
No affiliation info available
de Jong D
No affiliation info available
Mouradian MM
No affiliation info available
Chase TN
No affiliation info available

MeSH

AgedAntiparkinson AgentsCarbidopaDopamine AgonistsDopamine AntagonistsDopamine D2 Receptor AntagonistsDouble-Blind MethodDrug Therapy, CombinationErgolinesFemaleHumansLevodopaMaleMiddle AgedNeurologic ExaminationParkinson DiseaseReceptors, Dopamine D1Receptors, Dopamine D2Treatment Outcome

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8723141

Citation

Metman, L V., et al. "Effect of the Putative Dopamine D1 Agonist and D2 Antagonist FCE 23884 On Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 11, no. 3, 1996, pp. 257-60.
Metman LV, Blanchet PJ, de Jong D, et al. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Mov Disord. 1996;11(3):257-60.
Metman, L. V., Blanchet, P. J., de Jong, D., Mouradian, M. M., & Chase, T. N. (1996). Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 11(3), 257-60.
Metman LV, et al. Effect of the Putative Dopamine D1 Agonist and D2 Antagonist FCE 23884 On Parkinson's Disease. Mov Disord. 1996;11(3):257-60. PubMed PMID: 8723141.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. AU - Metman,L V, AU - Blanchet,P J, AU - de Jong,D, AU - Mouradian,M M, AU - Chase,T N, PY - 1996/5/1/pubmed PY - 1996/5/1/medline PY - 1996/5/1/entrez SP - 257 EP - 60 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 11 IS - 3 N2 - The ergoline derivative FCE 23,884 acts as a dopamine D1 agonist in untreated parkinsonian animals and as a D2 antagonist in animals whose dopamine system is intact or levodopa treated. To evaluate whether this dual action might benefit patients with Parkinson's disease (PD) who have developed levodopa-induced dyskinesias, the motor effects of FCE 23,884 were examined in seven such individuals using a double-blind, placebo-controlled design. At doses up to the maximum tolerated dose (3.5 +/- 0.5 mg), FCE 23,884 monotherapy did not affect parkinsonian severity. On the other hand, coadministration of FCE 23,884 with a mildly dyskinetic dose of levodopa, infused intravenously under steady-state conditions, reduced the antiparkinson response by 54 +/- 19% and tended to diminish dyskinesia severity. The results thus fail to suggest any useful role for FCE 23,884 in the symptomatic treatment of PD. Although D2 receptor blockade provided by FCE 23,884 antagonizes both the antiparkinson and dyskinesigenic responses to levodopa, the degree of D1 receptor stimulation appears insufficient to ameliorate parkinsonian symptomatology. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/8723141/Effect_of_the_putative_dopamine_D1_agonist_and_D2_antagonist_FCE_23884_on_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -